dental bone graft substitutes and barrier membrane Market

The Dental Bone Graft Substitute and Barrier Membrane market was valued at US$ 722.04 million in 2022 and is expected to reach a value of US$ 1,379.92 million by 2030; it is anticipated to record a CAGR of 8.4% from 2023 to 2030.

The growth of the market is attributed to the increasing burden of periodontal diseases and oral cancer and increased market development activities in dental bone graft substitute and barrier membrane market. However, high cost of products and delays in dental check-ups hinders the market growth.

Development strategies such as product launches, mergers and acquisitions, and expansions boost the growth of the dental bone graft substitute and barrier membrane market. In April 2023, ZimVie announced the launch of RegenerOss CC Allograft Particulate and RegenerOss Bone Graft Plug, which helped it extend its portfolio of biomaterials that are intended for filling extraction sockets and periodontal defects. The products are commercially available in North America. In May 2023, Straumann acquired GalvoSurge Dental AG, a Swiss medical device manufacturer. The acquired company specializes in implant care and maintenance solutions to support the treatment of peri-implantitis.

In October 2022, Geistlich, specialized in the regeneration of bone, cartilage, and tissue, acquired Lynch Biologics, US. The acquisition helped Geistlich Pharma to strengthen its portfolio by adding Lynch Biologics, LLC's leading GEM 21S product to it. GEM 21S is based on a growth factor that accelerates bone formation and wound healing. The companies further aim to innovate regenerative technologies in dentistry. In December 2022, Neoss Group, which designs, manufactures, and sells dental implant treatment products, opened a new sales office in the Nordic region. The facility commenced operations in the Nordic region on December 01, 2022, to support dental professionals and their patients. In January 2021, Dentsply Sirona acquired Datum Dental, a leading provider of innovative OSSIX regenerative solutions. The acquisition enabled Dentsply Sirona to acquire the strong OSSIX biomaterial portfolio of Datum Dental, Ltd. It also offered it access to the patented GLYMATRIX technology of Datum Dental Ltd. GLYMATRIX mimics the natural collagen cycle in the body, i.e., a biochemical process called glycation. GLYMATRIX forms the basis of OSSIX products for guided bone regeneration, as well as guided tissue regeneration.

Based on product, the dental bone graft substitute and barrier membrane market is segmented into dental bone graft substitutes and dental barrier membranes. The dental bone graft substitute segment held a larger market share in 2022 however, dental barrier membrane segment is anticipated to register a higher CAGR of 9.0% during the forecast period. Dental bone graft substitute is again segmented into allografts, autografts, xenografts, synthetic bone grafts, autografts, alloplasts, demineralized bone matrix (DBM), and others. Dental Barrier Membrane is again segmented into resorbable membrane and non-resorbable membrane.

In dentistry, barrier membranes improve the prognosis of periodontal tissue regeneration and bone augmentation associated with implant treatment. As bone defects heal, there is competition between soft tissue and bone-forming cells to invade the surgical site. Soft tissue cells generally migrate much faster than bone-forming cells.

Therefore, the main goal of barrier membranes is to allow selective cell repopulation and control the proliferation of different tissues during the healing process. Dental barrier membranes are designed to promote tissue regeneration and can be classified according to the biodegradability of the base material. Membranes used in guided bone regeneration (GBR) and transplantation can be of two main Products-non-resorbable and resorbable. Both the membranes differ in their biomaterial and physical properties, along with associated advantages and disadvantages for different clinical situations.

United States Food and Drug Administration (USFDA), Global Cancer Observatory (GCO), Centers for Disease Control and Prevention (CDC), and South African Dental Association (SADA) are a few key primary and secondary sources referred to while preparing the report on the dental bone graft substitute and barrier membrane market.